Developer docs
API playgroundTry for free, no card

Search company profiles

TVA Medical

Full company profile

uuid0003e1t

Namestring
TVA Medical
Legal namestring
Becton, Dickinson and Company
Websiteurl
tvamedical.com
Company typeenum
Private
Founded yearint
2008
Operating statusenum
Acquired
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersAustin, United States
HQ citystring
Austin
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Keyword5 values
endovascular fistula devices, hemodialysis vascular access, magnetic catheter systems, minimally invasive renal therapy, interventional vascular devices
Industry3 codes
1Vascular Access Devices (AV Grafts, Catheters, Fistula Accessories)
CodeHLAHAKAEPrimaryYes
2Vascular Access & Closure Devices (Sheaths, Guidewires, Closure Systems)
CodeHLAHAFAKPrimaryNo
3Endoscopic Therapeutic & Access Devices (Trocars, dilators, biopsy/ablation tools)
CodeHLAHADANPrimaryNo
NAICS code2 codes
  • Electromedical and Electrotherapeutic Apparatus Manufacturing334510
  • Navigational, Measuring, Electromedical, and Control Instruments Manufacturing3345
SIC code2 codes
  • Electromedical & Electrotherapeutic Apparatus3845
  • Surgical & Medical Instruments & Apparatus3841
Product category
Vascular Access Medical Devices
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Medical Device Sales
TypeHardware Sales
Description

Sale of the WavelinQ™ EndoAVF System consisting of 4F venous and arterial magnetic catheters, used with an electrosurgical unit (radiofrequency generator), ground pad, and electrosurgical pencil. Single-use catheters generate recurring revenue per procedure.

wavelinq.bd.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Personnel, Technology or R&D, Supply Chain, Operations, Marketing or Sales, Others
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 record
1WavelinQ™ EndoAVF System
Description

Endovascular arteriovenous fistula creation system for hemodialysis access in patients with end-stage kidney disease.

wavelinq.bd.com
Core offering1 text field

TVA Medical developed the WavelinQ EndoAVF System, an endovascular medical device platform that creates arteriovenous fistulas (AVF) for hemodialysis vascular access without open surgery. The system consists of 4F venous and arterial magnetic catheters used with an electrosurgical unit (RF generator), ground pad, and electrosurgical pencil; magnetic alignment pulls adjacent artery and vein together while a burst of RF energy creates the fistula connection. The product is sold to hospitals, dialysis centers, and interventionalists for use in patients with end-stage kidney disease requiring hemodialysis.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • 97% Procedure Technical Success Rate
+2 more records
Product overview1 text field

The WavelinQ™ EndoAVF System is a single medical device product for creating arteriovenous fistulas endovascularly. The system consists of 4F venous and 4F arterial magnetic catheters, used with an electrosurgical unit (radiofrequency generator), ground pad, and electrosurgical pencil. It represents a non-surgical alternative to traditional open surgery for AV fistula creation in ESKD patients requiring hemodialysis.

Product and service1 record
1WavelinQ EndoAVF System
Scale indicator4 records

Each record includes

Type, Value, Description, Source

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight3 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Medtronic markets the Ellipsys CVAC System, a direct competitor to WavelinQ for endovascular AV fistula creation in hemodialysis patients. Both companies target the same proceduralists and patient population with catheter-based, non-surgical AVF creation approaches.

TypeBroad incumbent
Description

BD acquired TVA Medical's technology through its acquisition of Bard and is the current owner and distributor of WavelinQ. As parent company and broad incumbent in vascular access and dialysis products, BD sets commercial strategy and competes against other major vascular access players.

TypeBroad incumbent
Description

Baxter invested in TVA via Baxter Ventures and is a major incumbent in dialysis (renal therapies) and vascular access. Baxter's broad portfolio in chronic kidney disease treatment overlaps with the patient population TVA's WavelinQ serves.

TypeBroad incumbent
Description

Boston Scientific invested in TVA's Series C and is a broad incumbent in interventional and vascular devices. While not a direct fistula-creation competitor, it operates in the same endovascular interventional space serving interventionalists who perform EndoAVF procedures.

TypeDirect peer
Description

Teleflex manufactures vascular access catheters and related devices used in interventional procedures, including those performed by proceduralists using endovascular systems like WavelinQ. Overlap in endovascular catheter technology and customer base.

TypeDirect peer
Description

AngioDynamics produces vascular access products including dialysis catheters and ports used in hemodialysis patients. Overlaps with TVA in vascular access for the ESKD patient population and catheter-based device delivery.

TypeBroad incumbent
Description

Fresenius is the world's largest dialysis services provider and manufactures vascular access products. As the dominant buyer-side player in hemodialysis, Fresenius influences adoption of fistula creation technologies including EndoAVF.

TypeBroad incumbent
Description

Abbott operates broadly in vascular and interventional devices following its St. Jude Medical and Cephea acquisitions. Provides catheter-based vascular access and closure products serving interventionalists who also perform WavelinQ EndoAVF procedures.

TypeEmerging player
Description

Penumbra is an emerging player in vascular intervention with catheter-based thrombectomy and access technologies. Operates in the same endovascular interventional space and serves some of the same proceduralist customers as WavelinQ.

TypeEmerging player
Description

Surmodics develops surface coating technologies and drug-coated balloon catheters used in vascular procedures including dialysis access maintenance. Adjacent to TVA's vascular access focus with overlapping customer base of interventionalists.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles4 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds4 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors6 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

TVA Medical

Vascular Access Medical Devicestvamedical.com

TVA Medical firmographics

Firmographics
Name
TVA Medical
Legal name
Becton, Dickinson and Company
Website
https://tvamedical.com
Company type
Private
Founded year
2008
Operating status
Acquired
Headcount range
11–50 employees
Ownership category
akta.pro rank

TVA Medical industry classification

Industry
Product category
Vascular Access Medical Devices
NAICS
Electromedical and Electrotherapeutic Apparatus Manufacturing (334510), Navigational, Measuring, Electromedical, and Control Instruments Manufacturing (3345)
SIC
Electromedical & Electrotherapeutic Apparatus (3845), Surgical & Medical Instruments & Apparatus (3841)
akta.pro primary industry
Vascular Access Devices (AV Grafts, Catheters, Fistula Accessories) (HLAHAKAE)
akta.pro secondary industries
Vascular Access & Closure Devices (Sheaths, Guidewires, Closure Systems) (HLAHAFAK), Endoscopic Therapeutic & Access Devices (Trocars, dilators, biopsy/ablation tools) (HLAHADAN)

Keywords

  • Endovascular fistula devices
  • Hemodialysis vascular access
  • Magnetic catheter systems
  • Minimally invasive renal therapy
  • Interventional vascular devices

Where TVA Medical is headquartered

Location

Headquarters

HQ city
Austin
HQ country
United States
HQ region
North America

Markets served

TVA Medical business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Technology or R&D, Supply Chain, Operations, Marketing or Sales, Others

Revenue model

  1. Medical Device Sales: Sale of the WavelinQ™ EndoAVF System consisting of 4F venous and arterial magnetic catheters, used with an electrosurgical unit (radiofrequency generator), ground pad, and electrosurgical pencil. Single-use catheters generate recurring revenue per procedure.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

TVA Medical product offering

Product offering

Core offering

TVA Medical developed the WavelinQ EndoAVF System, an endovascular medical device platform that creates arteriovenous fistulas (AVF) for hemodialysis vascular access without open surgery. The system consists of 4F venous and arterial magnetic catheters used with an electrosurgical unit (RF generator), ground pad, and electrosurgical pencil; magnetic alignment pulls adjacent artery and vein together while a burst of RF energy creates the fistula connection. The product is sold to hospitals, dialysis centers, and interventionalists for use in patients with end-stage kidney disease requiring hemodialysis.

Product overview

The WavelinQ™ EndoAVF System is a single medical device product for creating arteriovenous fistulas endovascularly. The system consists of 4F venous and 4F arterial magnetic catheters, used with an electrosurgical unit (radiofrequency generator), ground pad, and electrosurgical pencil. It represents a non-surgical alternative to traditional open surgery for AV fistula creation in ESKD patients requiring hemodialysis.

Differentiator

Problem solved

Functional benefit

Brands

  • WavelinQ™ EndoAVF System: Endovascular arteriovenous fistula creation system for hemodialysis access in patients with end-stage kidney disease.

Products and services

  • WavelinQ EndoAVF System

Quantifiable outcome

  • 97% Procedure Technical Success Rate
  • +2 more outcomes

Companies that use TVA Medical

Customer profile

Segments3 records

Ideal customer profiles2 records

TVA Medical technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

TVA Medical partnerships and signals

Strategic signal

Scale indicators4 records

Recent moves6 records

Expansion highlights3 records

TVA Medical competitors and assessment

Company assessment

Direct peers

  • Medtronic: Medtronic markets the Ellipsys CVAC System, a direct competitor to WavelinQ for endovascular AV fistula creation in hemodialysis patients. Both companies target the same proceduralists and patient population with catheter-based, non-surgical AVF creation approaches.
  • Teleflex: Teleflex manufactures vascular access catheters and related devices used in interventional procedures, including those performed by proceduralists using endovascular systems like WavelinQ. Overlap in endovascular catheter technology and customer base.
  • AngioDynamics: AngioDynamics produces vascular access products including dialysis catheters and ports used in hemodialysis patients. Overlaps with TVA in vascular access for the ESKD patient population and catheter-based device delivery.

Broad incumbents

  • Becton, Dickinson and Company (BD): BD acquired TVA Medical's technology through its acquisition of Bard and is the current owner and distributor of WavelinQ. As parent company and broad incumbent in vascular access and dialysis products, BD sets commercial strategy and competes against other major vascular access players.
  • Baxter International: Baxter invested in TVA via Baxter Ventures and is a major incumbent in dialysis (renal therapies) and vascular access. Baxter's broad portfolio in chronic kidney disease treatment overlaps with the patient population TVA's WavelinQ serves.
  • Boston Scientific: Boston Scientific invested in TVA's Series C and is a broad incumbent in interventional and vascular devices. While not a direct fistula-creation competitor, it operates in the same endovascular interventional space serving interventionalists who perform EndoAVF procedures.
  • Fresenius Medical Care: Fresenius is the world's largest dialysis services provider and manufactures vascular access products. As the dominant buyer-side player in hemodialysis, Fresenius influences adoption of fistula creation technologies including EndoAVF.
  • Abbott: Abbott operates broadly in vascular and interventional devices following its St. Jude Medical and Cephea acquisitions. Provides catheter-based vascular access and closure products serving interventionalists who also perform WavelinQ EndoAVF procedures.

Emerging players

  • Penumbra: Penumbra is an emerging player in vascular intervention with catheter-based thrombectomy and access technologies. Operates in the same endovascular interventional space and serves some of the same proceduralist customers as WavelinQ.
  • Surmodics: Surmodics develops surface coating technologies and drug-coated balloon catheters used in vascular procedures including dialysis access maintenance. Adjacent to TVA's vascular access focus with overlapping customer base of interventionalists.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks5 records

Key highlights7 records

Customer concentration

TVA Medical social profiles

Digital presence

TVA Medical financial estimates

Financial estimate

Revenue estimate

Valuation estimate

TVA Medical leadership team

Management profile

Number of profiles

Profiles4 records

TVA Medical funding detail

Funding detail

Funding overview

Funding rounds4 records

Investors6 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

TVA Medical M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about TVA Medical

What does TVA Medical do?

TVA Medical developed the WavelinQ EndoAVF System, an endovascular medical device platform that creates arteriovenous fistulas (AVF) for hemodialysis vascular access without open surgery. The system consists of 4F venous and arterial magnetic catheters used with an electrosurgical unit (RF generator), ground pad, and electrosurgical pencil; magnetic alignment pulls adjacent artery and vein together while a burst of RF energy creates the fistula connection. The product is sold to hospitals, dialysis centers, and interventionalists for use in patients with end-stage kidney disease requiring hemodialysis.

Is TVA Medical a public or private company?

TVA Medical is a private company. It is classified as corporate owned and is currently acquired.

When was TVA Medical founded?

TVA Medical was founded in 2008. It employs 11 to 50 people.

Where is TVA Medical based?

TVA Medical is headquartered in Austin, United States, in the North America region.

How does TVA Medical make money?

One revenue line is on record: medical Device Sales.

Who are TVA Medical's main competitors?

Direct peers on record are Medtronic, Teleflex and AngioDynamics. Broad incumbents are Becton, Dickinson and Company (BD), Baxter International, Boston Scientific, Fresenius Medical Care and Abbott. Emerging players are Penumbra and Surmodics.

Does TVA Medical have an API?

No public API is recorded for TVA Medical.

What industry is TVA Medical in?

TVA Medical's product category is Vascular Access Medical Devices. Its primary akta.pro industry code is HLAHAKAE, Vascular Access Devices (AV Grafts, Catheters, Fistula Accessories), with a secondary code of HLAHAFAK, Vascular Access & Closure Devices (Sheaths, Guidewires, Closure Systems). Its NAICS code is 334510 and its SIC code is 3845.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
PR NewswireNew Data Demonstrate Quality-Of-Life Improvements And Cost Savings For Endovascular Hemodialysis Access Vs. Traditional Open SurgeryA retrospective analysis comparing TVA Medical's everlinQ endoAVF System with traditional surgical arteriovenous fistula creation for hemodialysis access in end-stage renal disease patients was presented at ISPOR 2018 in Baltimore. The study found endoAVF patients had nearly double the days with a functioning fistula, spent significantly less time using central venous catheters (83 vs 261 days), required fewer interventions (0.55 vs 4.38), and incurred 90 percent lower related costs ($1,271 vs $13,031) in the first year. The everlinQ system is currently under FDA review in the United States and is not yet available for sale there, though it holds European CE Mark and Health Canada approvals.PR NewswireTVA Medical Receives CE Mark For Next-Generation everlinQ™ 4 endoAVF SystemTVA Medical, Inc. received CE Mark approval from the European Union for its everlinQ™ 4 endoAVF System, a 4 French catheter device that creates hemodialysis access using an endovascular technique without open surgery. In a clinical study, 97 percent of procedures were successful and 83 percent achieved fistula maturation. The first European procedure using the new system was performed by Dr. Tobias Steinke at Schön Klinik in Düsseldorf, Germany, and the company is now offering the system in Europe while pursuing FDA clearance for U.S. market access.PR NewswireExciting Clinical Results Presented On Endovascular Hemodialysis Access TechnologyTVA Medical presented clinical data at LINC 2017 in Leipzig, Germany on its everlinQ endoAVF System, reporting strong one-year results from the NEAT study including 91% fistula maturation and 84% patency. Real-world experience from two German centers showed 100% procedural success and 86% dialysis initiation within 56 days, while a smaller 4Fr system trial demonstrated 97% procedural success and 81% fistula maturation within 30 days. The endovascular technology offers a minimally invasive alternative to surgical arteriovenous fistulas, which carry failure rates as high as 60%, and is currently CE Mark approved in Europe while under FDA review in the United States.GlobeNewswireSquare 1 Bank Announces Credit Facility to TVA Medical, Inc.Square 1 Bank provided a $7 million credit facility to TVA Medical, a medical device company developing minimally invasive therapies for end-stage renal disease. Proceeds will fund ongoing operations and global clinical and market development initiatives. The company's catheter-based system aims to offer a less traumatic alternative to open surgery for hemodialysis patients.PR NewswireTVA Medical Receives Additional Reimbursement In Germany For The everlinQ™ endoAVF SystemTVA Medical's everlinQ endoAVF System has received NUB Status 1 approval from Germany's InEK, enabling 80+ leading German hospitals to negotiate additional insurance funding for the device. The approval represents the highest NUB status level and validates the clinical value of the technology, which is designed to create arteriovenous fistulas for hemodialysis patients using an endovascular approach. The company plans to begin controlled commercialization and a post-market study in Europe this year, though the device is not yet available in the United States.